Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,223 JPY | -1.07% |
|
+5.66% | -21.45% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.45% | 721M | - | ||
+48.54% | 56.61B | B- | ||
+36.75% | 39.25B | A | ||
-6.02% | 39.62B | B | ||
-6.90% | 28.28B | C | ||
+12.97% | 26.44B | B- | ||
-16.91% | 20.12B | B | ||
+31.71% | 12.48B | C+ | ||
+28.18% | 12.51B | B+ | ||
+0.38% | 12.2B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 2160 Stock
- Ratings GNI Group Ltd.